CRSP:NSD-Crispr Therapeutics AG (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 47.32

Change

0.00 (0.00)%

Market Cap

USD 4.03B

Volume

0.87M

Analyst Target

USD 95.21
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 35.29B
ARGX argenx NV ADR

N/A

USD 32.06B
MRNA Moderna Inc

N/A

USD 25.25B
BGNE BeiGene Ltd

N/A

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

N/A

USD 15.71B
SMMT Summit Therapeutics PLC

N/A

USD 15.35B
PCVX Vaxcyte Inc

N/A

USD 14.00B

ETFs Containing CRSP

XDNA 15.28 % 0.00 %

N/A

N/A
ARKG 6.42 % 0.75 %

N/A

N/A
ARKG:LSE ARK Genomic Revolution UC.. 6.25 % 0.00 %

N/A

USD 3.09M
ARCG:LSE ARK Genomic Revolution UC.. 6.20 % 0.00 %

N/A

USD 3.03M
ARKK ARK Innovation ETF 4.58 % 0.75 %

N/A

USD 5.85B
ARCK:LSE ARK Innovation UCITS ETF .. 4.38 % 0.00 %

N/A

USD 0.01B
ARKK:LSE ARK Innovation UCITS ETF .. 4.31 % 0.00 %

N/A

USD 0.01B
NXTE Investment Managers Serie.. 4.01 % 0.00 %

N/A

N/A
LS:CA 3.11 % 2.21 %

N/A

N/A
AIIQ 0.00 % 0.79 %

N/A

N/A
ERSX 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.41% 29% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.41% 29% F 27% F
Trailing 12 Months  
Capital Gain 4.25% 39% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.25% 39% F 44% F
Trailing 5 Years  
Capital Gain 15.44% 48% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.44% 48% F 56% F
Average Annual (5 Year Horizon)  
Capital Gain 16.49% N/A N/A 74% C
Dividend Return 16.49% N/A N/A 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 72.00% N/A N/A 24% F
Risk Adjusted Return 22.91% N/A N/A 56% F
Market Capitalization 4.03B 94% A 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.